Clinical trials: Hypofractionated Dose
PROSTATE CANCER
Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer
The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma…
- Trial name
- PROSINT (NCT02570919)
- Testing
- IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Fundacao Champalimaud
Cervical Cancer
Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer
This study is a randomized controlled trial designed to compare hypofractionated whole pelvic radiotherapy with conventional radiotherapy in patients with cervical cancer undergoing concurrent chemoradiotherapy.
- Trial name
- HYPOCx-iRex (NCT07605507)
- Testing
- Hypofractionated Radiotherapy, Conventional Radiotherapy, Concurrent chemotherapy once a week
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Siriraj Hospital
Carcinoma, Non-Small-Cell Lung
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of hypofractionated proton beam radiation therapy when given together with paclitaxel and carboplatin in treating patients with stage II-III non-small cell lung cancer.
- Trial name
- NCT02172846
- Testing
- Proton beam radiation therapy (PBT), Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40Gy/5 fractions/29 days) for the treatment of high risk prostate cancer currently being managed with primary androgen…
- Trial name
- pHART8 (NCT01505075)
- Testing
- Hypofractionated radiation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cervix Cancer, Radiotherapy, Adjuvant
Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer
To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after…
- Conditions
- Cervix Cancer, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Hypofractionated Dose
- Trial name
- NCT03239626
- Testing
- POHIM-RT
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Breast Cancer
Dose Escalated Concomitant Boost Radiotherapy for Early Breast Cancer
The goal of this prospective, single-arm, phase II, non-randomized trial is to evaluate an hypofractionation schedule with high dose simultaneous integrated tumor bed boost in early breast cancer patients.
- Trial name
- DEBoRa (NCT07021846)
- Testing
- hypofractionated radiotherapy with tumor bed boost
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer
Head and neck cancer in its advanced, incurable stage causes severe symptoms such as pain, trouble swallowing, and bleeding. Palliative radiation therapy is frequently used to relieve these symptoms and improve the patient's…
- Trial name
- QSSC-HN (NCT07823309)
- Testing
- Quad Shot Radiotherapy, Split Course Radiotherapy
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Prostate Cancer
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients.
- Trial name
- NCT02303327
- Testing
- EBRT + HDR brachytherapy boost, Hypofractionated Dose Escalation Radiotherapy, Androgen deprivation therapy
- Where
- 12 sites in Canada
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Carcinoma, Non-Small-Cell Lung
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy
The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer.
- Trial name
- NCT00256841
- Testing
- Chemotherapy, Radiation Therapy
- Where
- United States
- Sponsor
- Clinical Oncology Research Associates
Prostate Cancer
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in…
- Trial name
- NCT00667888
- Testing
- Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC.
- Trial name
- ANDROMEDA (NCT06141070)
- Testing
- Standard systemic therapy + radiotherapy, Standard systemic therapy
- Where
- 6 sites in Sweden
- Volunteers
- 240 people
- Sponsor
- Vastra Gotaland Region
Head and Neck Neoplasm
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy.
- Trial name
- DEHART (NCT04477759)
- Testing
- 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume < 700ml or estimated liver-GTV V5 < 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis…
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
- Trial name
- NCT06389422
- Testing
- Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage III Non-Small Cell Lung Cancer
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.
- Trial name
- NCT00938418
- Testing
- Dose escalated, accelerated, hypofractionated radiotherapy
- Where
- 3 sites in Singapore
- Volunteers
- 43 people
- Sponsor
- National University Hospital, Singapore
Prostate Cancer
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI).
- Trial name
- HypoElect (NCT06582446)
- Testing
- Androgen Deprivation Therapy (ADT) - Goserelin, High-Dose-Rate Interstitial Brachytherapy (HDR BRT), radiotherapy
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Prostate Cancer
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
- Trial name
- NCT03294889
- Testing
- Stereotactic body radition (SBRT)
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University Hospital, Geneva
Glioblastoma
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide…
- Trial name
- NCT02179086
- Testing
- Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
- Where
- 237 sites in United States, Canada
- Volunteers
- 624 people
- Sponsor
- NRG Oncology
Head and Neck Neoplasm
SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
To derive the maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell…
- Trial name
- NCT03402737
- Testing
- Stereotactic body radiotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 6 people
- Sponsor
- University Hospital, Ghent
Renal Cell Carcinoma, Renal Cell Carcinoma Metastatic
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
Prospective, randomised, feasibility study of patients with localised or metastatic renal cell carcinoma (RCC) comparing standard palliative dose radiotherapy to a high-dose hypofractionated regime.
- Trial name
- VIRTUAL (NCT06995664)
- Testing
- radiotherapy
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Royal Marsden NHS Foundation Trust